A pooled analysis of data from 1,359 patients in 4 phase II trials assessed the effects of evolocumab , a fully human monoclonal antibody to PCSK9 , on Lp ( a ) , the relationship between Lp ( a ) and lowering of low-density lipoprotein cholesterol ( LDL-C ) and apolipoprotein B , and the influence of background statin therapy .